Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study.

Clin Cancer Res · 2025 · PMC12434391 · PMID 40689871

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Following initial tarlatamab infusion, patients with DLL3+ tumors showed a trend toward greater margination of peripheral T cells versus patients with DLL3−/unknown tumors ( Fig. 3B ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.